Effects of excitotoxic lesions of the rat prefrontal cortex on CREB regulation and presynaptic markers of dopamine and amino acid function in the nucleus accumbens.
The present study investigated the effects of excitotoxic lesions of the prefrontal cortex (PFC) on dopamine (DA) and excitatory amino acid (EAA) function in the nucleus accumbens core using in vivo microdialysis in freely moving rats. As a postsynaptic marker of neuronal function, the nuclear levels of the transcriptional factor CREB and its active phosphorylated form, CREB-P, were measured in the ventral tegmental area (VTA), and in the core and shell subregions of the nucleus accumbens of sham and lesioned animals. PFC-lesioned animals exhibited a greater locomotor response to novelty and amphetamine administration (125-500 microg/kg i.v.). No change was observed in extracellular levels of glutamate or saturable d-aspartate binding (a marker for the high-affinity EAA transporter) in the nucleus accumbens of PFC-lesioned animals. Extracellular levels of DA were comparable in sham and lesioned animals under tonic conditions, however, following amphetamine administration, DA efflux was significantly attenuated in lesioned animals. No correlation was observed between microdialysate levels of amino acids and the attenuated dopaminergic response to amphetamine in lesioned animals. Further, no effect of the lesion was found on nuclear CREB protein in saline- and amphetamine-treated rats. The density of CREB-P immunoreactive nuclei, while remaining unchanged in the VTA, increased in the nucleus accumbens shell following amphetamine treatment in lesioned animals. The results show that an important modulatory role of the PFC on the behavioural response to novelty and amphetamine is associated with the level of immediate-early gene regulation rather than levels of extracellular DA and amino acids in the ventral striatum.
Dalley
J W
JW
Department of Experimental Psychology, University of Cambridge, UK. jwd20@cus.cam.ac.uk
Thomas
K L
KL
Howes
S R
SR
Tsai
T H
TH
Aparicio-Legarza
M I
MI
Reynolds
G P
GP
Everitt
B J
BJ
Robbins
T W
TW
D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001224:Aspartic Acid / Q000378:metabolism; D015415:Biomarkers; D017362:Cyclic AMP Response Element-Binding Protein / Q000502:physiology*; D004298:Dopamine / Q000502:physiology; D018846:Excitatory Amino Acids / Q000502:physiology; D005786:Gene Expression Regulation / Q000502:physiology*; D007150:Immunohistochemistry; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009419:Nerve Tissue Proteins / Q000502:physiology*; D009714:Nucleus Accumbens / Q000502:physiology*; D017397:Prefrontal Cortex / Q000502:physiology*; D017729:Presynaptic Terminals / Q000378:metabolism*; D051381:Rats
D015415:Biomarkers; D017362:Cyclic AMP Response Element-Binding Protein; D018846:Excitatory Amino Acids; D009419:Nerve Tissue Proteins; D001224:Aspartic Acid; D000661:Amphetamine; D004298:Dopamine